For the big mainline ad agencies, the recent creative consolidations at Pfizer and Johnson & Johnson are a big deal, but to their medical agency subsidiaries, they mostly represent a codification of where things stood to begin with.
Merck, one of the biggest spenders in pharma advertising, said it is consolidating its US creative business.
Pfizer awarded Ketchum a global assignment for Lipitor as the pharmaceutical company prepares for its top-selling drug to go off patent at the end of this year.
GlaxoSmithKline tapped Omnicom's PHD as media agency of record on all of its healthcare products, ousting incumbent WPP's MediaCom.
A sprawling review of GlaxoSmithKline's advertising business on US pharmaceutical brands is down to a shortlist of 20 agency networks.
Sanofi-Aventis put its global media buying and planning account up for review, a spokesperson for the company confirmed today.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.